Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ManevfiledCriticalManev
Priority to BG95739ApriorityCriticalpatent/BG95739A/en
Publication of BG95739ApublicationCriticalpatent/BG95739A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The means is produced by simplified technology. It potentiates the effect of the intralesion application of cyclophosphamide in solid malignant tumours at manyfold decrease of the effective dose of cyclophosphamide both in single and in general whole-course dose. The means contains polyoxyethylene (20) sobritan trioleate from 20 to 40% solution in physiological solution from 100.0 to 400 g/l, 0.5-0.8% CaCl2.H2O solution, "Decaris" (Levamysol) 2.5-5 mg/l in physiological solution and indomethacine 2.5-5 mg/l in physiological solution.
BG95739A1992-01-081992-01-08Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours
BG95739A
(en)
Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease